aripiprazole vs nirmatrelvir/ritonavir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aripiprazole and nirmatrelvir/ritonavir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, pimavanserin ↑ aripiprazole ↑ brexpiprazole ↑ cariprazine ↑ iloperidone ↑ lumateperone ↑ pimavanserin Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and pimavanserin is recommended.
Abilify
Paxlovid
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems. It can help to improve your mood, thinking, and behavior.
Paxlovid is a medicine used to treat mild to moderate COVID-19 in adults. It helps prevent severe illness, hospitalization, or death in people at high risk.
Aripiprazole is used to treat schizophrenia in adults and teens. It also treats irritability in children with autism. Additionally, it can treat Tourette's disorder.
Paxlovid treats mild to moderate COVID-19 in adults. You must be at high risk of your illness becoming severe. This includes needing to go to the hospital or possibly dying from COVID-19. Paxlovid is not for preventing COVID-19 before or after exposure.
Aripiprazole works by affecting the levels of certain chemicals in the brain. These chemicals, like dopamine and serotonin, can affect mood and behavior. By balancing these chemicals, aripiprazole helps to reduce symptoms of mental health conditions.
Paxlovid contains two medicines, nirmatrelvir and ritonavir. Nirmatrelvir stops the virus from multiplying in your body. Ritonavir helps nirmatrelvir stay in your body longer so it can work better.
- • Nausea
- • Vomiting
- • Constipation
- • Headache
- • Dizziness
- • Change in taste
- • Diarrhea
- Weight Increased 7,698
- Anxiety 4,993
- Fatigue 4,188
- Suicidal Ideation 3,991
- Depression 3,950
- COVID-19 22,774
- COVID-19 coming back 20,089
- Change in taste 7,316
- Diarrhea 4,003
- Feeling sick to your stomach 2,620
Aripiprazole may increase the risk of death in elderly patients who have psychosis related to dementia. It is not approved for this use. Antidepressants may increase the risk of suicidal thoughts and behaviors in children, teens, and young adults. Watch closely for worsening mood or suicidal thoughts.
Paxlovid can interact with many other medicines, causing serious or life-threatening problems. Before taking Paxlovid, tell your doctor about all the medicines you take. Your doctor may need to adjust the dose of your other medicines or monitor you more closely.
If you are pregnant or plan to become pregnant, talk to your doctor. Aripiprazole may cause withdrawal symptoms or other problems in newborns if taken during the third trimester. There is a pregnancy registry for women who take aripiprazole during pregnancy.
There is not enough information about nirmatrelvir's safety during pregnancy. Studies on ritonavir in pregnant women have not shown an increased risk of birth defects. Talk to your doctor about the risks and benefits of taking Paxlovid if you are pregnant or breastfeeding.
Also Compare, Nearby Drugs
Compare aripiprazole with
How to Read This aripiprazole vs nirmatrelvir/ritonavir Comparison
aripiprazole is classified in the Atypical Antipsychotic drug class, while nirmatrelvir/ritonavir sits within the Antiviral (Protease Inhibitor Combination) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aripiprazole has 24,820 submissions while nirmatrelvir/ritonavir has 56,802. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this medication prevents the body from clearing aripiprazole normally, leading to higher amounts of the drug in your system.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aripiprazole or nirmatrelvir/ritonavir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.